SBI Securities Co. Ltd. Makes New $236,000 Investment in Arbutus Biopharma Co. (NASDAQ:ABUS)

SBI Securities Co. Ltd. purchased a new position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 72,280 shares of the biopharmaceutical company's stock, valued at approximately $236,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. lifted its holdings in shares of Arbutus Biopharma by 218.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,212,246 shares of the biopharmaceutical company's stock valued at $4,667,000 after buying an additional 831,663 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Arbutus Biopharma in the 3rd quarter valued at about $754,000. Barclays PLC lifted its holdings in shares of Arbutus Biopharma by 466.3% in the 3rd quarter. Barclays PLC now owns 272,029 shares of the biopharmaceutical company's stock valued at $1,047,000 after buying an additional 223,995 shares during the period. State Street Corp lifted its holdings in shares of Arbutus Biopharma by 50.2% in the 3rd quarter. State Street Corp now owns 4,407,133 shares of the biopharmaceutical company's stock valued at $16,967,000 after buying an additional 1,472,652 shares during the period. Finally, Wellington Management Group LLP lifted its holdings in shares of Arbutus Biopharma by 4.6% in the 3rd quarter. Wellington Management Group LLP now owns 496,818 shares of the biopharmaceutical company's stock valued at $1,913,000 after buying an additional 21,807 shares during the period. Institutional investors and hedge funds own 43.79% of the company's stock.

Remove Ads

Arbutus Biopharma Stock Performance

Shares of Arbutus Biopharma stock traded down $0.06 on Friday, hitting $3.31. The company's stock had a trading volume of 1,191,920 shares, compared to its average volume of 1,021,355. Arbutus Biopharma Co. has a 1 year low of $2.30 and a 1 year high of $4.73. The firm has a fifty day moving average price of $3.34 and a 200-day moving average price of $3.64. The company has a market capitalization of $627.22 million, a price-to-earnings ratio of -7.70 and a beta of 1.93.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ABUS shares. HC Wainwright reissued a "buy" rating and issued a $5.00 price objective on shares of Arbutus Biopharma in a report on Tuesday, January 21st. StockNews.com raised Arbutus Biopharma from a "sell" rating to a "hold" rating in a report on Wednesday. Finally, Chardan Capital reissued a "buy" rating and issued a $5.00 price objective (up previously from $4.50) on shares of Arbutus Biopharma in a report on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $5.50.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.